AβPeptide Originated from Platelets Promises New Strategy in Anti-Alzheimer’s Drug Development
Year: 2017
Type: review
Abstract: The amyloid beta (Aβ) peptide and its deposits in the brain are known to be implicated in the neurodegeneration that occurs during Alzheimer’s disease (AD). Recently, alternative theories views concerning both the source of this peptide and its functions have been developed. It has been shown that, as in all other known types of amyloidosis, the production of Aβoriginates in blood cells or cells related to blood plasma, from which it can then spread from the blood to inside the brain, with the greatest concentration around brain blood vessels. In this review, we summarize research progress in this new area and outline some future perspectives. While it is still unclear whether the main source of Aβdeposits in AD is the blood, the possibility of blocking the chain of reactions that lead to constant Aβrelease from the blood to the brain may be exploited in an attempt to reduce the amyloid burden in AD. Solving the problem of Aβaccumulation in this way may provide an alternative strategy for developing anti-AD drugs.
Source: BioMed Research International
DOI: 10.1155/2017/3948360
Institution: Central University of the Caribbean
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,680
OpenAlex ID: W2753335514
